Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21195832 | 0.75 | HTT (0.37) | HTTPTK2ALDH1A1METAP2 | |
| SCHEMBL24786481 | 0.71 | BRD4 (0.35) | KDM4EALDH1A1HPGDBRD4LCK | |
| SCHEMBL17847965 | 0.71 | KDM4E (0.33) | HTTPTK2KDM4EALDH1A1HPGD | |
| SCHEMBL29285140 | 0.68 | LMNA (0.40) | KDM4EALDH1A1HPGDBRD4LCK | |
| SCHEMBL27185490 | 0.68 | AXL (0.38) | KDM4EALDH1A1HPGDBRD4LCK | |
| SCHEMBL20577534 | 0.67 | AXL (0.37) | KDM4EALDH1A1HPGDBRD4LCK | |
| SCHEMBL25241637 | 0.67 | AXL (0.37) | KDM4EALDH1A1HPGDBRD4LCK | |
| SCHEMBL24597178 | 0.67 | CA2 (0.42) | KDM4EALDH1A1HPGDBRD4LCK | |
| SCHEMBL31248181 | 0.66 | METAP2 (0.37) | HTTPTK2METAP2 | |
| SCHEMBL31243104 | 0.66 | HTT (0.33) | HTTPTK2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | DPYD, PDXK, TYMP | HTT 4448/4885PTK2 1985/4885KDM4E 3545/4885 |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | DPYD, TYMP, TOP2A | HTT 4062/4885PTK2 2277/4885KDM4E 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.